Tarsus Announces New Growth Focus at Investor Conference
Tarsus Pharmaceuticals will host a fireside chat at the BTIG 5th Annual Ophthalmology Day on December 1, with a...
Nanobiotix: Q3 2025 Cash Update & 2026 Clinical Outlook
Nanobiotix has closed a non-dilutive royalty financing with Healthcare Royalty valued up to $71 million, securing $50 million upfront...
Nanobiotix Q3 2025 Update & 2026 Clinical Outlook
Nanobiotix has closed a non-dilutive royalty financing with Healthcare Royalty worth up to $71 million, securing $50 million upfront...
Praxis’ Latest Epilepsy Portfolio Advancements at AES 2025
Praxis Precision Medicines will use the American Epilepsy Society meeting in Atlanta on December 5–9, 2025 to unveil new...
Day One Announces New 3-Year Ojemda FIREFLY-1 Trial Data
Day One Biopharmaceuticals reported three-year outcomes from the pivotal phase 2 FIREFLY-1 trial of tovorafenib (Ojemda) in pediatric low-grade...
Tonix Gets FDA Clearance for Phase 2 Depression Study
Tonix Pharmaceuticals has secured FDA clearance of an investigational new drug application to study TNX-102 SL (cyclobenzaprine HCl sublingual...
First Patient Randomized in AXPFLI HELIOS-3 Phase 3 Trial
Ocular Therapeutix has randomized the first patient in HELIOS-3, the second of two Phase 3 registrational trials evaluating AXPAXLI...
Rakovina to Present Second Abstract at Neuro-Oncology Meeting
Rakovina Therapeutics unveiled preclinical progress on a new class of CNS‑penetrant, PARP1‑selective inhibitors at the Society for Neuro‑Oncology 2025...
Scilex Announces $20.3 Million Gross Proceeds from Warrants
Scilex Holding Company has executed a warrant inducement deal expected to close around November 25, 2025, securing approximately $20.3...
Scilex Reveals Update on Datavault AI Meme Coin Distribution
Scilex Holding Company disclosed that DataVault AI intends to airdrop Dream Bowl 2026 meme coins to record holders of...